Cingulate is developing two (2) proprietary, first-line medications, CTX-1301 (Dexmethylphenidate) and CTX-1302 (Dextroamphetamine), via the accelerated 505 (b)(2) regulatory pathway for the treatment of ADHD seeking indications for all patient segments: children, adolescents and adults. The Company has completed its proof of concept trial in human subjects to validate the novel Target Product Profiles for both CTX-1301 and CTX-1302. After a planned submission of an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) in the first quarter of 2018, Cingulate intends to implement the full clinical plan for both CTX-1301 and CTX-1302 in 2018.
View Top Employees from Cingulate TherapeuticsWebsite | http://www.cingulatetherapeutics.com |
Revenue | $2 million |
Funding | $14.4 million |
Employees | 21 (21 on RocketReach) |
Founded | 2012 |
Address | 1901 W 47th Pl, 00, Ste 310, Westwood, Kansas 66205, US |
Phone | (913) 942-2300 |
Industry | Biotechnology, Pharmaceuticals, Pharmaceutical Manufacturing, Drug Discovery, Science and Engineering, Healthcare, Medical, Health Care |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies |
Looking for a particular Cingulate Therapeutics employee's phone or email?
The Cingulate Therapeutics annual revenue was $2 million in 2023.
Laurie Myers is the COO of Cingulate Therapeutics.
21 people are employed at Cingulate Therapeutics.
Cingulate Therapeutics is based in Westwood, Kansas.
The NAICS codes for Cingulate Therapeutics are [32, 32541, 325, 3254].
The SIC codes for Cingulate Therapeutics are [283, 28].